Author:
Kerwin Edward M.,Spangenthal Selwyn,Kollar Christine,St Rose Earl,Reisner Colin
Funder
Pearl Therapeutics Inc., a member of the AstraZeneca Group
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. 2018.
http://www.goldcopd.org
. Accessed 23 Jan 2018.
2. Lechuga-Ballesteros D, Noga B, Vehring R, Cummings RH, Dwivedi SK. Novel cosuspension metered-dose inhalers for the combination therapy of chronic obstructive pulmonary disease and asthma. Future Med Chem. 2011;3:1703–18.
3. Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. Langmuir. 2012;28:15015–23.
4. Doty A, Schroeder J, Vang K, Sommerville M, Taylor M, Flynn B, et al. Drug delivery from an innovative LAMA/LABA co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and reliability. AAPS PharmSciTech. 2018;19:837–44.
5. AstraZeneca Pharmaceuticals LP. Bevespi aerosphere™ prescribing information. 2017.
http://www.azpicentral.com/bevespi/bevespi_pi.pdf
. Accessed 23 Jan 2018.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献